Arcturus Therapeutics (ARCT) Set to Announce Quarterly Earnings on Wednesday

Arcturus Therapeutics (NASDAQ:ARCT) is scheduled to be posting its quarterly earnings results after the market closes on Wednesday, May 8th. Analysts expect Arcturus Therapeutics to post earnings of ($1.17) per share for the quarter. Parties interested in registering for the company’s conference call can do so using this link.

Arcturus Therapeutics (NASDAQ:ARCT) last announced its quarterly earnings results on Thursday, March 7th. The biotechnology company reported ($0.32) EPS for the quarter, topping the consensus estimate of ($1.69) by $1.37. Arcturus Therapeutics had a negative net margin of 15.65% and a negative return on equity of 18.22%. The firm had revenue of $33.99 million for the quarter, compared to analyst estimates of $64.14 million. On average, analysts expect Arcturus Therapeutics to post $-3 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Arcturus Therapeutics Price Performance

Shares of ARCT opened at $27.32 on Tuesday. The firm has a fifty day moving average price of $32.47 and a 200 day moving average price of $30.07. Arcturus Therapeutics has a 1-year low of $17.52 and a 1-year high of $43.81.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the company. William Blair reissued an “outperform” rating on shares of Arcturus Therapeutics in a research report on Friday, March 8th. Citigroup lifted their target price on shares of Arcturus Therapeutics from $40.00 to $48.00 and gave the company a “buy” rating in a report on Thursday, February 8th. Finally, HC Wainwright reiterated a “buy” rating and set a $60.00 price target on shares of Arcturus Therapeutics in a research note on Wednesday, March 20th. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat.com, Arcturus Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $61.33.

Insider Buying and Selling at Arcturus Therapeutics

In other news, COO Pad Chivukula sold 17,435 shares of the stock in a transaction dated Monday, March 25th. The shares were sold at an average price of $35.02, for a total value of $610,573.70. Following the completion of the transaction, the chief operating officer now owns 473,448 shares in the company, valued at approximately $16,580,148.96. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 13.80% of the stock is owned by corporate insiders.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.